These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma. Laud K; Marian C; Avril MF; Barrois M; Chompret A; Goldstein AM; Tucker MA; Clark PA; Peters G; Chaudru V; Demenais F; Spatz A; Smith MW; Lenoir GM; Bressac-de Paillerets B; J Med Genet; 2006 Jan; 43(1):39-47. PubMed ID: 15937071 [TBL] [Abstract][Full Text] [Related]
32. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Holland EA; Schmid H; Kefford RF; Mann GJ Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427 [TBL] [Abstract][Full Text] [Related]
33. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. FitzGerald MG; Harkin DP; Silva-Arrieta S; MacDonald DJ; Lucchina LC; Unsal H; O'Neill E; Koh J; Finkelstein DM; Isselbacher KJ; Sober AJ; Haber DA Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8541-5. PubMed ID: 8710906 [TBL] [Abstract][Full Text] [Related]
34. Rarity of CDK4 germline mutations in familial melanoma. Goldstein AM; Chidambaram A; Halpern A; Holly EA; Guerry IV D; Sagebiel R; Elder DE; Tucker MA Melanoma Res; 2002 Feb; 12(1):51-5. PubMed ID: 11828258 [TBL] [Abstract][Full Text] [Related]
35. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865 [TBL] [Abstract][Full Text] [Related]
36. Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations. Vignoli M; Scaini MC; Ghiorzo P; Sestini R; Bruno W; Menin C; Gensini F; Piazzini M; Testori A; Manoukian S; Orlando C; D'Andrea E; Bianchi-Scarrà G; Genuardi M Melanoma Res; 2008 Dec; 18(6):431-7. PubMed ID: 19011513 [TBL] [Abstract][Full Text] [Related]
37. Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases. Aoude LG; Gartside M; Johansson P; Palmer JM; Symmons J; Martin NG; Montgomery GW; Hayward NK Twin Res Hum Genet; 2015 Apr; 18(2):126-33. PubMed ID: 25787093 [TBL] [Abstract][Full Text] [Related]
38. [Recommendations for genetic testing and management of individuals genetically at-risk of cutaneous melanoma]. Avril MF; Bahadoran P; Cabaret O; Caron O; de la Fouchardière A; Demenais F; Desjardins L; Frébourg T; Hammel P; Leccia MT; Lesueur F; Mahé E; Martin L; Maubec E; Remenieras A; Richard S; Robert C; Soufir N; Stoppa-Lyonnet D; Thomas L; Vabres P; Bressac-de Paillerets B Ann Dermatol Venereol; 2015 Jan; 142(1):26-36. PubMed ID: 25600792 [TBL] [Abstract][Full Text] [Related]
39. Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma. Hearle N; Damato BE; Humphreys J; Wixey J; Green H; Stone J; Easton DF; Houlston RS Invest Ophthalmol Vis Sci; 2003 Feb; 44(2):458-62. PubMed ID: 12556369 [TBL] [Abstract][Full Text] [Related]
40. Genetic variants in DNA repair genes and the risk of cutaneous malignant melanoma in melanoma-prone families with/without CDKN2A mutations. Liang XS; Pfeiffer RM; Wheeler W; Maeder D; Burdette L; Yeager M; Chanock S; Tucker MA; Goldstein AM; Yang XR Int J Cancer; 2012 May; 130(9):2062-6. PubMed ID: 21671477 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]